[KRAS status versus EGFR status in lung cancer therapy]
- PMID: 20034873
- DOI: 10.1684/bdc.2009.0999
[KRAS status versus EGFR status in lung cancer therapy]
Abstract
Interest for development of molecular biomarkers tends to increase in clinical management of lung cancer. Indeed implementation in clinics of new molecules targeting epithelial growth factor (EGFR) such as erlotinib or gefitinib, rise several questions regarding the potential value of EGFR and KRAS mutations to predict therapeutic response. In the current review, we discuss the utilization of such biomarkers regarding published clinical data and the possibilities versus limitations associated with analyses performed in molecular laboratory on a daily setting basis.
Similar articles
-
Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.J Thorac Oncol. 2008 Dec;3(12):1446-53. doi: 10.1097/JTO.0b013e31818ddcaa. J Thorac Oncol. 2008. PMID: 19057271 Clinical Trial.
-
Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.J Clin Oncol. 2011 Nov 1;29(31):4113-20. doi: 10.1200/JCO.2010.31.8162. Epub 2011 Oct 3. J Clin Oncol. 2011. PMID: 21969500 Clinical Trial.
-
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).J Thorac Oncol. 2012 Oct;7(10):1490-502. doi: 10.1097/JTO.0b013e318265b2b5. J Thorac Oncol. 2012. PMID: 22982650
-
KRAS mutation: should we test for it, and does it matter?J Clin Oncol. 2013 Mar 10;31(8):1112-21. doi: 10.1200/JCO.2012.43.0454. Epub 2013 Feb 11. J Clin Oncol. 2013. PMID: 23401440 Review.
-
Defining clinically relevant molecular subsets of lung cancer.Cancer Chemother Pharmacol. 2006 Nov;58 Suppl 1:s11-5. doi: 10.1007/s00280-006-0310-x. Cancer Chemother Pharmacol. 2006. PMID: 17093937 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous